CNR1 and metabolic dysfunction-associated steatotic liver disease: Although CB2 agonism and antagonism have shown conflicting results regarding their role in NAFLD, CB1 antagonism has demonstrated therapeutic benefits especially when central nervous system penetration has been minimized or eliminated [35,37,54].